(Q57132840)

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

DHT Concentrations in Human Prostate Cancer Tissue*

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Molecular determinants of resistance to antiandrogen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Novel Steroidal Inhibitors of Human Cytochrome P45017.alpha.-Hydroxylase-C17,20-lyase): Potential Agents for the Treatment of Prostatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Blockade of testicular and adrenal androgens in prostate cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Overview of dehydroepiandrosterone biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Human 3 beta-hydroxysteroid dehydrogenase/delta 5----4isomerase from placenta: expression in nonsteroidogenic cells of a protein that catalyzes the dehydrogenation/isomerization of C21 and C19 steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Steroid 5 alpha-reductase: two genes/two enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Androgen biosynthetic pathways in the human prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Dihydrotestosterone synthesis from adrenal precursors does not involve testosterone in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

5alpha-androstane-3alpha,17beta-diol is formed in tammar wallaby pouch young testes by a pathway involving 5alpha-pregnane-3alpha,17alpha-diol-20-one as a key intermediate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

"Getting from here to there"--mechanisms and limitations to the activation of the androgen receptor in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Expression cloning and characterization of oxidative 17beta- and 3alpha-hydroxysteroid dehydrogenases from rat and human prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Identification of the major oxidative 3alpha-hydroxysteroid dehydrogenase in human prostate that converts 5alpha-androstane-3alpha,17beta-diol to 5alpha-dihydrotestosterone: a potential therapeutic target for androgen-dependent disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Pathways of chemotherapy resistance in castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

Increased survival with enzalutamide in prostate cancer after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

DHT bypasses testosterone to drive progression to castration resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

The backdoor pathway to dihydrotestosterone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.175

The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro.

31 March 2020

1 reference

12 December 2020

Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays.

1 reference

12 December 2020

Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

1 reference

12 December 2020

The enzymatic reduction of delta 4-3-ketosteroids

1 reference

12 December 2020